Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Hideaki SUGIYAMA"'
Autor:
Mana YONEKURA, Yuto MATSUURA, Kuniaki KATO, Takuya IWASAWA, Mina OSUG, Tatsuya OHNUMA, Tomoyo KOSAKA, Hideaki SUGIYAMA, Naoteru KOIZUMI
Publikováno v:
Zen Nihon Shinkyu Gakkai zasshi (Journal of the Japan Society of Acupuncture and Moxibustion). 72:91-100
Autor:
Ling Han, Xu Fang, Hideaki Sugiyama, Qi Zhang, Qiong Huang, Kexiang Yan, Thomas S. McCormick, Kevin D. Cooper
Publikováno v:
The Australasian Journal of Dermatology
Background CD39 and CD73 are two novel cell surface markers of CD25highFoxp3+ regulatory T-cells (Tregs). Concordant expression of these two ectoenzymes not only discriminate Tregs from other cell populations, but also generates pericellular adenosin
Autor:
Kevin D. Cooper, Ally Khan Somani, Katalin Ferenczi, Joseph Chen, Pamela Aubert, Jennifer Ohtola, Anita C. Gilliam, Thomas S. McCormick, S. Matsuyama, Margaret Kessler, I. Yeh, Hideaki Sugiyama
Publikováno v:
British Journal of Dermatology. 163:564-571
Primary cutaneous T-cell lymphomas (CTCLs) represent a heterogeneous group of non-Hodgkin lymphomas characterized by clonal proliferation of neoplastic T cells and strikingly increased epidermal homing mechanism.1–3 Primary CTCLs such as mycosis fu
Autor:
Wendy A. Goodman, Thomas S. McCormick, Jessica V. Massari, Kevin D. Cooper, Alan D. Levine, Hideaki Sugiyama
Publikováno v:
The Journal of Immunology. 183:3170-3176
T memory/effector cells (Tmem/eff) isolated from psoriatic patients are chronically activated and poorly suppressed by regulatory T cells (Treg). The proinflammatory cytokine IL-6, which signals through Stat3, allows escape of Tmem/eff cells from Tre
Publikováno v:
Clinics in Dermatology. 26:503-508
Alefacept is the first biologic agent approved by the US Food and Drug Administration for the treatment of psoriasis. To date, more than 1000 patients with moderate to severe psoriasis have been enrolled in phase III clinical trials of alefacept. Mor
Autor:
Akiko Nagasaka, Shinji Shimada, Yasuhiro Nakamura, N Ando, Hideaki Sugiyama, Reiko Kitamura, Naotaka Shibagaki, Hiroyuki Matsue, Tatsuyoshi Kawamura, Katsuhiko Tsukamoto
Publikováno v:
Dermatology. 214:210-220
Background: It remains to be determined whether pemphigus vulgaris (PV), an autoimmune blistering disease, has a reduction and/or dysfunction of CD4+CD25high regulatory T (Treg) cells. Objectives: To evaluate the frequency and phenotypes of Treg cell
Autor:
Thomas S. McCormick, Eiko Toichi, Rolland Gyulai, Edina Garaczi, Hideaki Sugiyama, Shinji Shimada, Seth R. Stevens, Kevin D. Cooper
Publikováno v:
The Journal of Immunology. 174:164-173
The balance between regulatory and effector functions is important for maintaining efficient immune responses, while avoiding autoimmunity. The inflammatory skin disease psoriasis is sustained by the ongoing activation of pathogenic effector T cells.
Autor:
Taiichi Kanda, Hidetoshi Kashihara, Hideaki Sugiyama, Koichi Shimura, Masaru Shioikari, Masaki Tamura
Publikováno v:
Japanese journal of MHTS. 26:246-249
Autor:
Akira Shimizu, Tatsuyoshi Kawamura, Masutaka Furue, Yoshiharu Fukuda, Hideaki Sugiyama, Masahiko Tabata, K. Tamaki, Naoto Ohtake
Publikováno v:
Skin Cancer. 12:143-146
A 35-year-old man had a slowly enlarging tumor that has been presented for more than ten years on his occipital region.The nodule had been excised and a radiation therapy had been performed at a different hospital ten years ago. Eight years later, th
Autor:
David C. Soler, Thomas S. McCormick, Jessica V. Massari, Andrew Young, Hideaki Sugiyama, Kevin D. Cooper
Publikováno v:
Clinical immunology (Orlando, Fla.). 149(1)
CCR5 expression on CD4+CD25highFoxp3+ regulatory T cells (Tregs) has been reported to be crucial for limiting Th1 inflammation associated with autoimmunity and bacterial infections. We inquired whether abnormalities in chemokine receptors expressed o